[1] Younossi ZM. Non-alcoholic fatty liver disease-A global public health perspective. J Hepatol, 2019, 70(3):531-544. [2] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018, 24(7):908-922. [3] Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond), 2019, 133(22):2245-2264. [4] Makri E, Goulas A, Polyzos SA. Epidemiology,pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res, 2021, 52(1):25-37. [5] 赵锐豪,郑鹏远,梅璐,等.降脂益生菌对非酒精性脂肪性肝病小鼠肠黏膜屏障功能和肠道菌群的影响及机制.中华微生物学和免疫学杂志,2019,39(8):620-627. [6] Abenavoli L, Scarpellini E, Pellicano R, et al. Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease. Minerva Med, 2020, 111(6):526-528. [7] 郭静,叶琳琳,郭玉琴,等.从“浊阴凝痞”视角探讨非酒精性脂肪肝病辨治思路.中华中医药杂志,2020,35(4):1885-1887. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):177-186. [9] 陈丽丽,符茂雄,刘正金,等.非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨.实用肝脏病杂志,2020,23(5):658-661. [10] Cotter TG, Rinella M. Nonalcoholicfatty liver disease 2020: the state of the disease. Gastroenterology, 2020, 158(7):1851-1864. [11] Fernando DH, Forbes JM, Angus PW,et al. Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. Int J Mol Sci, 2019, 20(20):5037. [12] Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut, 2020, 69(10):1877-1884. [13] Chen YH, Wu WK, Wu MS. Microbiota-associated therapy for non-alcoholic steatohepatitis-induced liver cancer: a review. Int J Mol Sci, 2020, 21(17):5999. [14] Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol, 2020, 17(5):279-297. [15] Zhou X, Liu B, Ning Q, et al. Combination of Huanglian Jiedudecoction and erlotinib delays growth and improves sensitivity of EGFR-mutated NSCLC cells in vitro and in vivo via STAT3/Bcl-2 signaling. Oncol Rep, 2021, 45(1):217-229. [16] Wang Y, Tai YL, Zhao D, et al. Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways. Cells, 2021, 10(2):210. [17] 张婷,宋厚盼,林也,等.黄连解毒汤之“清热解毒”药效与作用机制研究进展.中华中医药学刊,2020,38(11):135-139. [18] Huang T, Liu Y, Zhang C. Pharmacokinetics and bioavailability enhancement of baicalin:a review. Eur J Drug Metab Pharmacokinet, 2019, 44(2):159-168. [19] Huang X, Wang L, Yue R, et al. Large dosage Huangqin (Scutellaria) and Huanglian (Rhizoma Coptidis) for T2DM:a protocol of systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore), 2020, 99(38):e22032. [20] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20(2):395. |